Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Down 55.0% in August

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the target of a significant decrease in short interest in August. As of August 31st, there was short interest totaling 20,320 shares, a decrease of 55.0% from the August 15th total of 45,169 shares. Approximately 1.0% of the shares of the company are short sold. Based on an average daily volume of 31,148 shares, the days-to-cover ratio is currently 0.7 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Xenetic Biosciences

An institutional investor recently raised its stake in Xenetic Biosciences stock. Renaissance Technologies LLC boosted its stake in Xenetic Biosciences, Inc. (NASDAQ:XBIO) by 516.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 178,509 shares of the company’s stock after buying an additional 149,559 shares during the quarter. Renaissance Technologies LLC owned approximately 7.80% of Xenetic Biosciences worth $387,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 15.12% of the company’s stock.

Xenetic Biosciences Trading Up 1.7%

NASDAQ XBIO traded up $0.07 on Monday, reaching $3.96. The company’s stock had a trading volume of 9,240 shares, compared to its average volume of 27,945. The firm has a market cap of $9.08 million, a PE ratio of -3.42 and a beta of 2.23. The business has a 50-day moving average price of $3.29 and a 200 day moving average price of $3.08. Xenetic Biosciences has a 52 week low of $1.90 and a 52 week high of $13.93.

Xenetic Biosciences (NASDAQ:XBIO) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) EPS for the quarter. The business had revenue of $0.66 million for the quarter. Xenetic Biosciences had a negative return on equity of 40.62% and a negative net margin of 75.90%.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.